Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Thibaut Davy-MendezSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8505-9268
Sonia NapravnikSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9032-3713
Brenna C HoganBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-7100-8910
Joseph J EronSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kelly A GeboBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-4010-398X
Keri N AlthoffBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Richard D MooreBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0001-8250-5069
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.ORCID 0000-0001-9322-1395
Michael A HorbergKaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA.ORCID 0000-0002-6971-7646
M John GillSouthern Alberta HIV Clinic, Calgary, Alberta, Canada.
Jonathan A ColasantiSchool of Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0536-9769
Ank NijhawanUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0003-0522-4110
Maile Y KarrisSchool of Medicine, University of California San Diego, San Diego, California, USA.
Marina B KleinFaculty of Medicine, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-3063-8430
Raynell LangCumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-0268-4680
Catherine R LeskoBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-1717-2592
George A YendewaSchool of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-8474-1812
Gregory D KirkBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-7829-1405
Kathleen A McGinnisDepartment of Internal Medicine, VA Connecticut Healthcare, West Haven, Connecticut, USA.ORCID 0000-0003-4844-3372
Stephen A BerryBloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA)
Funding
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Studies of Ocular Complications of AIDS - Coordinating CenterU10EY008057 · NEI · JOHNS HOPKINS UNIVERSITY · PI VAN NATTA, MARK L · 1988 to 2012
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
backgroundHospitalization causes among persons with HIV (PWH) have shifted to non-AIDS conditions, but the complete disease profile of hospitalized PWH has not been well described. To inform hospitalization and readmission prevention efforts, we examined non-AIDS disease prevalence among PWH hospitalized in 4 US cohorts and 1 Canadian cohort.
methodsAmong PWH with ≥1 hospitalization from 2008 to 2018, we used log-binomial regression with generalized estimating equations to estimate trends in the annual prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease (CKD) stage ≥3, and multimorbidity (≥2 and ≥3 conditions), defined using longitudinal diagnosis, medication, and laboratory data.
resultsWe examined 6781 hospitalized PWH who were 75% cisgender men, 40% White, and 38% Black. From 2008 to 2018, the proportion of PWH in care who had ≥1 hospitalization decreased from 9.6% to 6.3%. Age- and cohort-adjusted prevalence increased for hyperlipidemia (relative change per year: 3.6% [95% CI: 2.5%-4.7%]), diabetes mellitus (2.8% [1.3%-4.4%]), CKD (3.3% [1.7%-4.9%]), ≥2 conditions (1.3% [0.6%-2.0%]), and ≥3 conditions (3.0% [1.7%-4.3%]), decreased for HCV infection (-2.0% [-3.0%, -0.9%]), and remained stable for HBV infection (1.6% [-1.1%, 4.3%]) and hypertension (0.4% [-0.2%, 1.1%]).
conclusionsHospitalized PWH had an increasing burden of several non-AIDS conditions and multimorbidity not accounted for by aging alone. Further work is needed to understand these conditions' role in hospitalization risk among PWH. Our findings reinforce that hospital discharge planning in PWH should include efforts to ensure chronic conditions are adequately managed.
Indexed as
HIV InfectionsHospitalizationAdultAgedCanadaDiabetes MellitusFemaleHepatitis BHepatitis CHumansHyperlipidemiasHypertensionMaleMiddle AgedPrevalenceRenal Insufficiency, ChronicagingcomorbidityHIVhyperlipidemiahypertension
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With HIV in the United States and Canada, 2008-2018. · full record | OpenQuestion